marijuana stock news

GW Pharmaceuticals to Present at Bank of America Merrill Lynch 2015 Healthcare Conference

GW Pharmaceuticals plc (GWPH) (GWP.L) “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced that Justin Gover, GW’s Chief Executive Officer, is scheduled to present at the Bank of America Merrill Lynch 2015 Healthcare Conference to be held at Encore at the Wynn in Las Vegas, NV on Tuesday, 12 May, 2015 at 4:20 p.m. PT.

A live audio webcast of the presentation will be available through GW’s corporate website in the investor relations section from the investor’s calendar of events page at www.gwpharm.com. A replay will be available soon after the live presentation.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 27 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes Sativex in Phase 3 clinical development as a potential treatment of pain associated with advanced cancer, as well as compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, and schizophrenia. For further information, please visit www.gwpharm.com.

Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Stephen Schultz, VP Investor Relations (U.S.) 917 280 2424 / 401 500 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen (UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin 646 378 2900
Contact:

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

CLS Holdings USA, Inc.’s (CLSH) Oasis Dispensary Featured in February 2019 Edition of A&E Magazine

CLS Holdings’ Oasis Dispensary Featured in February 2019 Edition of A&E Magazine…

Trulieve Cannabis Corp. (TCNNF) to Hold Third Quarter 2022 Results Conference Call on November 9, 2022

Trulieve Cannabis Corp. to Hold Third Quarter 2022 Results Conference Call on…

Medical Marijuana, Inc. (MJNA) Subsidiary Kannaway® Expands Into Russia

Medical Marijuana, Inc. Subsidiary Kannaway® Expands Into Russia, Kazakhstan and Kyrgyzstan Medical…

AbbVie Inc. (ABBV) Reports Full-Year and Fourth-Quarter 2022 Financial Results

AbbVie Reports Full-Year and Fourth-Quarter 2022 Financial Results AbbVie (NYSE:ABBV) announced financial…